CDMO Leadership ABL has a long-standing CDMO service division focused on GMP cell banks and viral vectors from bench to Phase I/II, presenting a strong value proposition for biopharma clients advancing gene therapies, immunotherapies, viral vaccines, and oncolytic viruses.

End‑to‑End Capabilities With expertise spanning product development, GMP manufacturing, bulk drug substance, fill/finish, process development, and assay development and release testing, ABL can be a one-stop partner to accelerate preclinical through early clinical programs.

Clinical Development Support ABL positions itself as a seamless extension of client teams to advance candidate vaccines and therapeutics through preclinical and clinical development, offering potential for long‑term collaboration and larger project scopes.

Industry Positioning Founded in 1961 with a history of federal government collaboration, ABL's credibility in life sciences and diagnostics development can help target government research programs, funded collaborations, and public‑sector partnerships.

Growth Readiness With a sizable workforce and a revenue band aligned with mid‑market biopharma, ABL appears ready for customers seeking scalable CDMO capacity for growing gene therapy and viral vector programs, including mid‑stage to early‑phase manufacturing needs.